Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Phase 3

Withdrawn

• Conditions: Glaucoma, Open-Angle; Ocular Hypertension

• Registration Number: NCT00283764
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-01-26
• Study First Submitted QC: 2006-01-26
• Study First Posted: 2006-01-30
• Status Verified: 2015-03
• Last Update Submitted: 2021-02-01
• Last Update Posted: 2021-02-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria

• History of closed/barely open anterior chamber angle or a history of angle closure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Intra-ocular pressure (IOP) level in the study eye.

Secondary Outcome Measures

Name	Time	Method
Successful eyedrop self-deliveries
Ease of eyedrop administration
Change in safety assessments throughout the study period
Subject preference for the method of drop delivery